Oxygen Biotherapeutics (OXBT) 3.65 $OXBT
Oxygen Biotherapeutics Announces Fiscal Year 2014 Financial Results
Business Wire - Tue Jul 29, 7:01AM CDT
--Activated sites for Phase 3 LEVO-CTS trial for levosimendan in LCOS in the U.S., with data expected in first calendar quarter of 2016
Oxygen Biotherapeutics to Announce Fourth Quarter and Fiscal Year 2014 Financial Results on July 29, 2014
Business Wire - Tue Jul 22, 7:32PM CDT
Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, announced today that the Company will host a conference call and live audio webcast on Tuesday, July 29, 2014, at 8:30 a.m. ET to report financial results for the fourth quarter and fiscal year ended April 30, 2014, and provide a corporate update.
Recent Scientific Publications Highlight Potential Benefits of Levosimendan in Cardiac Surgery and Additional Critical Care Conditions
Business Wire - Wed Jul 09, 7:30AM CDT
Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today highlighted three recent review articles examining the current clinical use of levosimendan and its potential to address a wide range of critical care conditions.
Worldwide Market for Blood Products, Blood Testing, Blood Equipment, and Synthetic Blood Products to 2017
M2 - Mon Jun 30, 2:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/45fldn/blood_the) has announced the addition of the "Blood: The Worldwide Market for Blood Products, Blood Testing, Blood Equipment, and Synthetic Blood Products" report to their offering. The Worldwide Market for Blood Products, Blood Testing, Blood Equipment, and Synthetic Blood Products provides an analysis of all the key market segments involved in this industry, including products, equipment and testing. The global blood industry has experienced strong growth in recent years and although this brisk expansion will slow somewhat as products continue to mature and pricing pressures increase, growth will remain solid though 2017 as a result of aging populations in the U.S., Europe and Japan; ongoing technology advancements/new product introductions and indications; expansion of health coverage in the U.S. via health care reform; and continued strong promotion of blood donation by collection agencies. A variety of infectious agents can be present in blood, including viruses (e.g., HIV-1, hepatitis B and C, HTLV, West Nile virus), bacteria, protozoans, Chagas disease, Lyme Disease and prions (e.g., the agent of variant Crueutzfeldt-Jakob disease, which is the human form of mad cow disease). As of 2013, the main residual risk is due to hepatitis B virus - ranging from 10 in Spain to 1.6 per million donations in France and Germany although other conditions such as variant Creutzfeldt-Jakob disease (vCJD) or HIV may pose high risk in certain regions. Testing markets covered include: - Blood Banking and Plasmapheresis Testing - Blood Typing - Human Immunodeficiency Virus (HIV) Testing - Hepatitis A Virus Testing - Hepatitis B Virus Testing - Hepatitis C Virus Testing - Human T-Cell Leukemia Virus Testing - West Nile Virus Testing - Other Safety Testing Blood products covered in the report include: - Red Blood Cells (RBCs) - Immunoglobulins - Albumin - Other Plasma Products - Synthetic HBOC and PFC Agents - Recombinant Factors Blood equipment revenues and forecasts are provided for: - Blood Collection Equipment - Automated Blood Collection Equipment In addition to complete market data, including forecasts to 2017, the study reports: - Product demand estimates by region - Collection and transfusion estimates - High-blood-loss procedure estimates - Product pricing - Reimbursement rates - Epidemiology of key conditions requiring blood products - Products on the market and in development The report also profiles key companies in the industry, including: - AABB - Abbott Laboratories - America's Blood Centers - American Red Cross - Baxter International - Bio-Rad Laboratories - BioTime Inc. - Gen-Probe Inc. /Hologic - Fenwal/Fresenius Kabi - Grifols Biologicals, Inc. - Novartis Diagnostics - Novo Nordisk A/S - OPK BioTech - Oxygen Biotherapeutics - Perftoran - Roche - Sanguine Corp. For more information visit http://www.researchandmarkets.com/research/45fldn/blood_the
Oxygen Biotherapeutics (OXBT) is Oversold: Can It Recover? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jun 04, 8:04AM CDT
Oxygen Biotherapeutics (OXBT) is Oversold: Can It Recover?
Oxygen Biotherapeutics Announces Formation of Steering Committee for Phase 3 LEVO-CTS Trial of Levosimendan
Business Wire - Mon Jun 02, 8:34AM CDT
--- Trial to start in third quarter of 2014 -
Oxygen Biotherapeutics Up on FDA News - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 2:13PM CDT
Clinical hold on Oxycyte has been lifted by the FDA.
Oxygen Biotherapeutics Inc. Provides an Update on Communication with the FDA Regarding Oxycyte Development Program
Business Wire - Mon Mar 31, 7:31AM CDT
Oxygen Biotherapeutics, Inc., (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, announced today that it has received written confirmation from the Food and Drug Administration (FDA) that the clinical hold on the Oxycyte development program has been lifted.
Oxygen Biotherapeutics prices public offering at USD5.60 per share
M2 - Wed Mar 19, 6:04AM CDT
Pharmaceutical company Oxygen Biotherapeutics (NasdaqCM:OXBT) disclosed on Tuesday that it has priced a public offering of its common stock at USD5.60 per share.
Oxygen Biotherapeutics Prices $52 Million Underwritten Offering
Business Wire - Tue Mar 18, 7:45AM CDT
Oxygen Biotherapeutics, Inc., (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, announced today that it has priced an underwritten public offering of shares of common stock at a public offering price of $5.60 per share for gross proceeds of approximately $52 million, prior to deducting underwriting discounts and commissions and offering expenses payable by the Company. The Company has also granted the underwriters a 45-day option to purchase up to an additional 1,392,857 shares of common stock to cover over-allotments, if any.
Oxygen Biotherapeutics to issue common stock in public offering
M2 - Tue Mar 18, 6:37AM CDT
US-based pharmaceutical company Oxygen Biotherapeutics (NasdaqCM:OXBT) said on Monday that it intends to start a public offering of its common stock.
Oxygen Biotherapeutics Announces Proposed Public Offering
Business Wire - Mon Mar 17, 3:05PM CDT
Oxygen Biotherapeutics, Inc., (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, announced today its intention, subject to market and other conditions, to commence a public offering of its common stock. The Company intends to use the net proceeds received from the offering for furthering its clinical trials and efforts to obtain regulatory approval for Levosimendan and Oxycyte, developing its other product candidates, supporting manufacturing of Levosimendan and Oxycyte, research and development and general corporate purposes.
OxySure's Improving Financials & Operational Milestones Paint a Bullish Picture
ACCESSWIRE - Mon Mar 10, 8:01AM CDT
Whitefish, MT / March 10, 2014 / The healthcare industry has been attracting record amounts of capital in 2014, driven by biotechnology and pharmaceutical companies bringing new products to market. In fact, more than half of all money flowing into U.S. sector-focused ETFs, or $4.06 billion through February 28th, was placed in healthcare ETFs, according to data compiled by Bloomberg.
Financial Results, FDA Reviews, and Share Price Movements - Analyst Notes on Insys, Oxygen Biotherapeutics, Acorda, Air Methods, and AcelRx
PR Newswire - Fri Mar 07, 7:00AM CST
Today, Analysts Review released its analysts' notes regarding INSYS Therapeutics, Inc. (NASDAQ: INSY), Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), Acorda Therapeutics, Inc. (NASDAQ: ACOR), Air Methods Corp. (NASDAQ: AIRM), and AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
WEALTHMAKERS.COM Issues Report on Oxygen Biotherapeutics
M2 - Thu Mar 06, 7:27AM CST
WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued a new research report today on Oxygen Biotherapeutics (NASDAQ: OXBT). The report highlights the short term bullish pattern that has emerged, the SqueezeTrigger Price of $5.12 and the projected fundamental target of $10.50 per share.
Technical Notes on Top Gainers: Vipshop Holdings, Oxygen Biotherapeutics, JinkoSolar Holding, SunPower and BPZ Resources
PR Newswire - Wed Mar 05, 9:18AM CST
The US markets saw a positive sentiment on Tuesday, March 04, 2014, as the NASDAQ Composite closed at 4,351.97, climbing 1.75%, the Dow Jones Industrial Average ended the session at 16,395.88, up 1.41% and the S&P 500 edged 1.53% higher to finish the bullish trading session at 1,873.91. During the session healthy gains in the Financial, Health Care and Materials sectors positively impacted the broader market. A number of stocks saw large movements, including Vipshop Holdings Ltd (NYSE: VIPS), Oxygen Biotherapeutics Inc. (NASDAQ: OXBT), JinkoSolar Holding Company Ltd (NYSE: JKS), SunPower Corporation (NASDAQ: SPWR), and BPZ Resources Inc. (NYSE: BPZ), which were amongst the top gainers for the session. Free research on these five companies can be accessed at:
5 Stocks Ready to Explode Higher
at The Street - Wed Feb 26, 2:03PM CST
Here's a look at five stocks with potentially explosive chart patterns.
Research and Markets: Panel Builders Market: Research & Analysis UK 2014-2018
Business Wire - Thu Feb 20, 4:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/5b4nzh/panel_builders) has announced the addition of the "Panel Builders Market: Research & Analysis UK 2014-2018" report to their offering.
Biotech Breakthroughs Brings Powerful Cancer Testing and Drugs to Market
PR Newswire - Tue Feb 18, 6:00AM CST
New trial confirms MetaSite Breast test's ability to predict breast cancer metastasis. MetaSite Breast would allow doctors and patients to customize breast cancer treatment based on the cancer's probability of metastasizing.
Oxygen Biotherapeutics Announces Fiscal Year 2014 Financial Results
Business Wire - Tue Jul 29, 7:01AM CDT
--Activated sites for Phase 3 LEVO-CTS trial for levosimendan in LCOS in the U.S., with data expected in first calendar quarter of 2016
Oxygen Biotherapeutics to Announce Fourth Quarter and Fiscal Year 2014 Financial Results on July 29, 2014
Business Wire - Tue Jul 22, 7:32PM CDT
Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, announced today that the Company will host a conference call and live audio webcast on Tuesday, July 29, 2014, at 8:30 a.m. ET to report financial results for the fourth quarter and fiscal year ended April 30, 2014, and provide a corporate update.
Recent Scientific Publications Highlight Potential Benefits of Levosimendan in Cardiac Surgery and Additional Critical Care Conditions
Business Wire - Wed Jul 09, 7:30AM CDT
Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today highlighted three recent review articles examining the current clinical use of levosimendan and its potential to address a wide range of critical care conditions.
Worldwide Market for Blood Products, Blood Testing, Blood Equipment, and Synthetic Blood Products to 2017
M2 - Mon Jun 30, 2:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/45fldn/blood_the) has announced the addition of the "Blood: The Worldwide Market for Blood Products, Blood Testing, Blood Equipment, and Synthetic Blood Products" report to their offering. The Worldwide Market for Blood Products, Blood Testing, Blood Equipment, and Synthetic Blood Products provides an analysis of all the key market segments involved in this industry, including products, equipment and testing. The global blood industry has experienced strong growth in recent years and although this brisk expansion will slow somewhat as products continue to mature and pricing pressures increase, growth will remain solid though 2017 as a result of aging populations in the U.S., Europe and Japan; ongoing technology advancements/new product introductions and indications; expansion of health coverage in the U.S. via health care reform; and continued strong promotion of blood donation by collection agencies. A variety of infectious agents can be present in blood, including viruses (e.g., HIV-1, hepatitis B and C, HTLV, West Nile virus), bacteria, protozoans, Chagas disease, Lyme Disease and prions (e.g., the agent of variant Crueutzfeldt-Jakob disease, which is the human form of mad cow disease). As of 2013, the main residual risk is due to hepatitis B virus - ranging from 10 in Spain to 1.6 per million donations in France and Germany although other conditions such as variant Creutzfeldt-Jakob disease (vCJD) or HIV may pose high risk in certain regions. Testing markets covered include: - Blood Banking and Plasmapheresis Testing - Blood Typing - Human Immunodeficiency Virus (HIV) Testing - Hepatitis A Virus Testing - Hepatitis B Virus Testing - Hepatitis C Virus Testing - Human T-Cell Leukemia Virus Testing - West Nile Virus Testing - Other Safety Testing Blood products covered in the report include: - Red Blood Cells (RBCs) - Immunoglobulins - Albumin - Other Plasma Products - Synthetic HBOC and PFC Agents - Recombinant Factors Blood equipment revenues and forecasts are provided for: - Blood Collection Equipment - Automated Blood Collection Equipment In addition to complete market data, including forecasts to 2017, the study reports: - Product demand estimates by region - Collection and transfusion estimates - High-blood-loss procedure estimates - Product pricing - Reimbursement rates - Epidemiology of key conditions requiring blood products - Products on the market and in development The report also profiles key companies in the industry, including: - AABB - Abbott Laboratories - America's Blood Centers - American Red Cross - Baxter International - Bio-Rad Laboratories - BioTime Inc. - Gen-Probe Inc. /Hologic - Fenwal/Fresenius Kabi - Grifols Biologicals, Inc. - Novartis Diagnostics - Novo Nordisk A/S - OPK BioTech - Oxygen Biotherapeutics - Perftoran - Roche - Sanguine Corp. For more information visit http://www.researchandmarkets.com/research/45fldn/blood_the
Oxygen Biotherapeutics (OXBT) is Oversold: Can It Recover? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jun 04, 8:04AM CDT
Oxygen Biotherapeutics (OXBT) is Oversold: Can It Recover?
Oxygen Biotherapeutics Announces Formation of Steering Committee for Phase 3 LEVO-CTS Trial of Levosimendan
Business Wire - Mon Jun 02, 8:34AM CDT
--- Trial to start in third quarter of 2014 -
Oxygen Biotherapeutics Up on FDA News - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 2:13PM CDT
Clinical hold on Oxycyte has been lifted by the FDA.
Oxygen Biotherapeutics Inc. Provides an Update on Communication with the FDA Regarding Oxycyte Development Program
Business Wire - Mon Mar 31, 7:31AM CDT
Oxygen Biotherapeutics, Inc., (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, announced today that it has received written confirmation from the Food and Drug Administration (FDA) that the clinical hold on the Oxycyte development program has been lifted.
Oxygen Biotherapeutics prices public offering at USD5.60 per share
M2 - Wed Mar 19, 6:04AM CDT
Pharmaceutical company Oxygen Biotherapeutics (NasdaqCM:OXBT) disclosed on Tuesday that it has priced a public offering of its common stock at USD5.60 per share.
Oxygen Biotherapeutics Prices $52 Million Underwritten Offering
Business Wire - Tue Mar 18, 7:45AM CDT
Oxygen Biotherapeutics, Inc., (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, announced today that it has priced an underwritten public offering of shares of common stock at a public offering price of $5.60 per share for gross proceeds of approximately $52 million, prior to deducting underwriting discounts and commissions and offering expenses payable by the Company. The Company has also granted the underwriters a 45-day option to purchase up to an additional 1,392,857 shares of common stock to cover over-allotments, if any.
Oxygen Biotherapeutics to issue common stock in public offering
M2 - Tue Mar 18, 6:37AM CDT
US-based pharmaceutical company Oxygen Biotherapeutics (NasdaqCM:OXBT) said on Monday that it intends to start a public offering of its common stock.
Oxygen Biotherapeutics Announces Proposed Public Offering
Business Wire - Mon Mar 17, 3:05PM CDT
Oxygen Biotherapeutics, Inc., (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, announced today its intention, subject to market and other conditions, to commence a public offering of its common stock. The Company intends to use the net proceeds received from the offering for furthering its clinical trials and efforts to obtain regulatory approval for Levosimendan and Oxycyte, developing its other product candidates, supporting manufacturing of Levosimendan and Oxycyte, research and development and general corporate purposes.
OxySure's Improving Financials & Operational Milestones Paint a Bullish Picture
ACCESSWIRE - Mon Mar 10, 8:01AM CDT
Whitefish, MT / March 10, 2014 / The healthcare industry has been attracting record amounts of capital in 2014, driven by biotechnology and pharmaceutical companies bringing new products to market. In fact, more than half of all money flowing into U.S. sector-focused ETFs, or $4.06 billion through February 28th, was placed in healthcare ETFs, according to data compiled by Bloomberg.
Financial Results, FDA Reviews, and Share Price Movements - Analyst Notes on Insys, Oxygen Biotherapeutics, Acorda, Air Methods, and AcelRx
PR Newswire - Fri Mar 07, 7:00AM CST
Today, Analysts Review released its analysts' notes regarding INSYS Therapeutics, Inc. (NASDAQ: INSY), Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), Acorda Therapeutics, Inc. (NASDAQ: ACOR), Air Methods Corp. (NASDAQ: AIRM), and AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
WEALTHMAKERS.COM Issues Report on Oxygen Biotherapeutics
M2 - Thu Mar 06, 7:27AM CST
WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued a new research report today on Oxygen Biotherapeutics (NASDAQ: OXBT). The report highlights the short term bullish pattern that has emerged, the SqueezeTrigger Price of $5.12 and the projected fundamental target of $10.50 per share.
Technical Notes on Top Gainers: Vipshop Holdings, Oxygen Biotherapeutics, JinkoSolar Holding, SunPower and BPZ Resources
PR Newswire - Wed Mar 05, 9:18AM CST
The US markets saw a positive sentiment on Tuesday, March 04, 2014, as the NASDAQ Composite closed at 4,351.97, climbing 1.75%, the Dow Jones Industrial Average ended the session at 16,395.88, up 1.41% and the S&P 500 edged 1.53% higher to finish the bullish trading session at 1,873.91. During the session healthy gains in the Financial, Health Care and Materials sectors positively impacted the broader market. A number of stocks saw large movements, including Vipshop Holdings Ltd (NYSE: VIPS), Oxygen Biotherapeutics Inc. (NASDAQ: OXBT), JinkoSolar Holding Company Ltd (NYSE: JKS), SunPower Corporation (NASDAQ: SPWR), and BPZ Resources Inc. (NYSE: BPZ), which were amongst the top gainers for the session. Free research on these five companies can be accessed at:
5 Stocks Ready to Explode Higher
at The Street - Wed Feb 26, 2:03PM CST
Here's a look at five stocks with potentially explosive chart patterns.
Research and Markets: Panel Builders Market: Research & Analysis UK 2014-2018
Business Wire - Thu Feb 20, 4:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/5b4nzh/panel_builders) has announced the addition of the "Panel Builders Market: Research & Analysis UK 2014-2018" report to their offering.
Biotech Breakthroughs Brings Powerful Cancer Testing and Drugs to Market
PR Newswire - Tue Feb 18, 6:00AM CST
New trial confirms MetaSite Breast test's ability to predict breast cancer metastasis. MetaSite Breast would allow doctors and patients to customize breast cancer treatment based on the cancer's probability of metastasizing.
